German hubs selected for BII cardiometabolic research initiative
BioInnovation Institute (BII) has selected Munich and Berlin as the locations for its German activities under the CardioMetabolic Bridge (CMB) initiative.
The expansion marks another important milestone in BII’s ambition to build a connected European innovation ecosystem dedicated to accelerating the development of new treatments for cardiometabolic diseases.
Supported by the Novo Nordisk Foundation, CardioMetabolic Bridge is a pan-European initiative designed to bridge the gap between academic research and commercial drug development.
With Munich and Berlin joining London as key locations in the network, BII aims to strengthen access to outstanding scientific research, clinical expertise, entrepreneurial talent and industry networks across Europe.
Germany is home to a strong life science and medical research ecosystem, with world-class universities, hospitals, research institutions and biotech companies. The selection of Munich and Berlin reflects the strength and complementary capabilities of the two innovation environments and their potential to contribute to the next generation of cardiometabolic therapies.
“Germany has outstanding scientific capabilities and some of Europe’s most dynamic life science ecosystems. We see significant opportunities in both Munich and Berlin to connect excellent research with the entrepreneurial expertise, infrastructure and industry networks needed to bring new therapies closer to patients. Establishing our presence in these two locations is an important step in expanding CardioMetabolic Bridge and strengthening Europe’s ability to turn scientific discoveries into meaningful healthcare solutions,” said Jens Nielsen, CEO of BioInnovation Institute.
CardioMetabolic Bridge will provide selected research projects with early-stage funding, access to laboratory infrastructure, scientific and commercial mentoring, drug discovery and development expertise, and connections to investors and industry partners.
The initiative focuses on research addressing cardiometabolic diseases, including obesity, type 2 diabetes and cardiovascular disease, with the ambition of accelerating the development of next-generation therapeutics and supporting the creation of new biotech companies.
